Dr. Robert Whitfield discusses a new marker called Oxylipin Tinho for diagnosing breast implant illness, which routine inflammation tests like sed rate and CRP fail to detect. He's working with companies to evaluate better diagnostic tests.
Oxylipin Tinho
2024
Sed rate and CRP
Everybody asks me, do I have one test that will, you know, tell them that they have breast implant illness and we'll use this as a teaser. I've been in conversations with one of the scientists who recently published a paper about something called Oxylipin Tinho. Fancy name. And if everybody will remember the name of that, that is something we're going to talk to companies about looking at and getting test results for. So we have a call coming up with some companies. I don't need anybody bombarding this company, so I'm not going to mention them by name. But we are, rest assured, working to try to figure out better ways to both establish, you know, levels of inflammation, because the standard things we use, like sed rate, CRP for everyday evaluations don't really measure up in this situation. So it's really hard. If Casey came in to me five years ago and said, you know, I feel like crap and I don't know what's going on. And she was just on her routine, you know, follow up, and wanted to have us do an exam for her to make sure everything was fine with her, her implants. We would have not had the forethought to suggest anything based on, you know, that time period. You know, fast Forward now it's 2024.
